ENDPOINTS

BioMarin makes Phase 3 buy, paying $270M for rare disea...

BioMarin, multiple quarters into its portfolio refinement, is inking a small acq...

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notche...

Plus, news about vTv Therapeutics, Dynavax, Aura Biosciences and ArkBio: FDA...

Novo Nordisk CEO to step down, timeline for successor u...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down, the company announced...

It's been three months without a biotech IPO

The last time a biotech went public on a US stock exchange, people were buying f...

Novo Nordisk’s global obesity leader is moving on; Flag...

→ Leo Pharma is doing an extensive revamp of its leadership team as it splits pr...

Top RFK Jr. advisor dares drugmakers over threats to dr...

NEW YORK — Calley Means, a special White House employee and top advisor to HHS S...

Regeneron gets $400M+ jury win in Amgen cholesterol dru...

A Delaware jury on Thursday said Regeneron should get more than $400 million in ...

Eisai says Leqembi sales are expanding steadily in US

Eisai executives said on Thursday that Leqembi sales and shipments in the US are...

New CBER chief is readying 'massive framework' for vacc...

Vinay Prasad may have just started as the new director of the FDA's biologics ce...

Eli Lilly teams up with RNA editing biotech for hearing...

Eli Lilly is building out its gene therapy pipeline for hearing loss through a n...

Philadelphia doctors treat infant with first custom CRI...

PHILADELPHIA — Soon after Kyle Patrick Muldoon, Jr. was born in August 2024, his...

FDA warns Mayne Pharma over 'misleading' birth control ...

The FDA’s drug promotion office is calling out Australia's Mayne Pharma for maki...

Bristol Myers CEO says America’s biopharma pole positio...

NEW YORK — Bristol Myers Squibb CEO Chris Boerner said America’s role as the glo...

Pathos AI collects $365M to fuel data-driven oncology s...

Pathos AI, seeking to upend cancer drug development with artificial intelligence...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.